Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NICE's balance sheet 2006-07

NICE's balance sheet 2006-07

NICE's balance sheet 2006-07
Of 28 appraisals issued in 2006 and 2007, NICE recommended 40 treatments for coverage on the NHS and seven were rejected. However, of the drugs recommended, only half were recommended for use in line with the approved indication. With a few exceptions, restrictions or denials generally are associated with treatments where the cost/QALY (quality-adjusted life year) begins to approach £30,000. (A) Company model deemed not sufficiently robust to provide a QALY range acceptable to NICE. Source: NICE website
Appraisal [date] Product(s) Label indication NICE recommendation Effect on access Cost/ QALY
TA111 [9/07] Aricept donepezil Treat mild to moderate dementia in Alzheimer's disease (AD) Recommended to treat moderate AD only, defined as Mini Mental State Examination (MMSE) score 10-20 Restricted £23,000-£35,000
Reminyl galantamine (Razadyne) Treat mild to moderate dementia in AD Recommended to treat moderate AD only, defined as MMSE score 10-20 Restricted £23,000-£35,000
Exelon rivastigmine Treat mild to moderate dementia in AD Recommended to treat moderate AD only, defined as MMSE score 10-20 Restricted £23,000-£35,000
Ebixa memantine (Namenda, Axura) Treat moderate to severe dementia in AD Not recommended except

Read the full 1876 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE